CERVOMED INC. - COMMON

CervoMed to Participate in Upcoming Investor Conferences

07 11 2024 08:30:00 提供 Nasdaq GlobeNewswire

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

04 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

29 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

15 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

27 8 2024 08:30:00 提供 Nasdaq GlobeNewswire

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

11 7 2024 08:51:12 提供 Nasdaq GlobeNewswire

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

24 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

11 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Appoint William Elder as Chief Financial Officer

20 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

28 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 3 2024 08:30:00 提供 Nasdaq GlobeNewswire